Sildenafil citrate does not affect cardiac contractility in human or dog heart

Current Medical Research and Opinion

Volumn 19, Issue 8, 2003, Pages 747-752

  Corbin, Jackie ^a   Rannels, Stephen ^a   Neal, Doss ^a   Chang, Paul ^a   Grimes, Kennard ^a   Beasley, Alfreda ^a   Francis, Sharron ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac contractility; Erectile dysfunction; Phosphodiesterase; Sildenafil citrate

Indexed keywords

ADRENALIN; BICARBONATE; BUFFER; CARBON DIOXIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; INOTROPIC AGENT; ISOBUTYLMETHYLXANTHINE; OXYGEN; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; RINGER SOLUTION; SILDENAFIL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG SELECTIVITY; ELECTROSTIMULATION; ENZYME ACTIVITY; EVALUATION; EXPERIMENT; HEART ATRIUM APPENDAGE; HEART ATRIUM CONTRACTION; HEART ATRIUM MUSCLE; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MUSCLE EXCITATION; NONHUMAN; PH; PROTEIN ANALYSIS; RECORDING; SPECIES COMPARISON; TEMPERATURE; TENSION; TIME; TISSUE SLICE;

ANIMALS; DOGS; HUMANS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 0345708290     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002522     Document Type: Article

References (33)

1. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52
2. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998;159:2164-71
3. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999;274:13729-32
4. Jeremy JY, Ballard SA, Naylor AM, Miller MAW, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997;79:958-63
5. Moreland RB, Goldstein I, Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 1998;62:309-18
6. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
7. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997;9:123-6
8. Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994;140:930-7
9. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology 2002;60 (Suppl 2B):12-27
10. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999;83:13C-20C
11. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-6
12. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-51
13. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002;287:719-25
14. Fox KM, Thadani U, Ma PTS, et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 2003; submitted
15. Patrizi R, Leonardo F, Pelliccia F, et al. Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers. Ital Heart J 2001;2:841-4
16. Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. J Hypertens 2000;18:1-5
17. Kloner RA. Cardiovascular safety profile for sildenafil: Sexual Dysfunction in Medicine 2000;1:66-9
18. Cheitlin MD, Hutter AM, Brindis RG, Ganz P, Kaul S, Russell RO, Zusman RM. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999;99:168-77
19. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panel. Am J Cardiol 2000;86:175-81
20. Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002;60(Suppl 2B):67-90
21. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83:35C-44C
22. Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000;36:25-31
23. Stief CG, Uckert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, Jonas U. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 2000;55:146-50
24. Senzaki H, Smith CJ, Juang GJ, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 2001;15:1718-26
25. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002;56:453-9
26. Corbin JD, Gettys TW, Blackmore PF, Beebe SJ, Francis SH, Glass DB, Redmon JB, Sheorain VS, Landiss LR. Purification and assay of cAMP, cGMP, and cyclic nucleotide analogs in cells treated with cyclic nucleotide analogs. Methods Enzymol 1988;159:74-82
27. Gopal VK, Francis SH, Corbin JD. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 2001;268:3304-12
28. Sugden PH, Corbin JD. Adenosine 3′:5′-cyclic monophosphate-binding proteins in bovine and rat tissues. Biochem J 1976;159:423-7
29. Corbin JD, Sugden PH, Lincoln TM, Keely SL. Compartmentalization of adenosine 3′:5′-monophosphate and adenosine 3′:5′ -monophosphate-dependent protein kinase in heart tissue. J Biol Chem 1977;252:3854-61
30. Gillies H, Roblin D, Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 2002;86:131-41
31. Sugiyama A, Satoh Y, Shiina H, Takahara A, Yoneyama M, Hashimoto K. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J Cardiovasc Pharmacol 2001;38:940-6
32. Parums DV, Charlton RG, Johnson N, Cindrove T, Skepper J, Phillips S, Ridden J, Burslem F. Immunohistochemical (IHC), in situ hybridisation (ISH) and biochemical characterisation of phosphodiesterase type 5 (PDE5) in normal and ischaemic human cardiac tissue (PDE5). Eur Heart J 2000;21:616
33. Corbin JD, Francis SH, Osterloh IH. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue [letter]. Urology 2000;56:545